Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation
These findings suggest that rituximab has superior effectiveness compared to cladribine during a median follow-up of 4.5 years.
Authors
- Einar August Høgestøl (ORCID: https://orcid.org/0000-0001-8446-2111)
- Jon Michael Gran (ORCID: https://orcid.org/0000-0002-6964-4969)
- Øivind Torkildsen (ORCID: https://orcid.org/0000-0001-5294-2866)
- Marton König (ORCID: https://orcid.org/0000-0001-6242-9804)
- Gro Owren Nygaard (ORCID: https://orcid.org/0000-0002-4913-8567)
- Brit Ellen Rød (ORCID: https://orcid.org/0000-0003-2200-1525)
- Kjell‐Morten Myhr (ORCID: https://orcid.org/0000-0002-0980-510X)
- Mathias H. Øverås (ORCID: https://orcid.org/0000-0001-7358-2644)
- Stig Wergeland (ORCID: https://orcid.org/0000-0002-7645-7686)
- Kjetil Bjørnevik (ORCID: https://orcid.org/0000-0002-2892-6986)
Institutions
- Oslo University Hospital (NO)
- Harvard University (US)
- University of Oslo (NO)
- Haukeland University Hospital (NO)
- University of Bergen (NO)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1177/13524585251342727
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- EkstraStiftelsen Helse og Rehabilitering (Stiftelsen Dam)
- Norges Forskningsråd